Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies

被引：50
作者：
French, Jena D. [1 ,2 ]
机构：
[1] Univ Colorado Denver, Dept Med, Div Endocrinol Metab & Diabet, Denver, CO 80204 USA
[2] Univ Colorado Denver, Ctr Canc, Aurora, CO USA
来源：
NATURE REVIEWS ENDOCRINOLOGY | 2020年 / 16卷 / 11期
关键词：
TUMOR-ASSOCIATED MACROPHAGES; T-CELL RECOGNITION; ASSOCIATION GUIDELINES; ANTIGEN PRESENTATION; SERUM THYROGLOBULIN; PREDICTS RESPONSE; SUPPRESSOR-CELLS; NEXT-GENERATION; IMMUNE-RESPONSE; BRAF INHIBITOR;
D O I：
10.1038/s41574-020-0398-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
With immune checkpoint blockade (ICB) technologies increasingly being used in cancer immunotherapy, early data suggest that ICB therapies could be effective in thyroid cancer. This Review discusses our current knowledge of the immune response in thyroid cancers, the latest and ongoing immune-based approaches and the future of immunotherapies in thyroid cancer. In the past decade, the field of cancer immunotherapy has been revolutionized by immune checkpoint blockade (ICB) technologies. Success across a broad spectrum of cancers has led to a paradigm shift in therapy for patients with advanced cancer. Early data are now accumulating in progressive thyroid cancers treated with single-agent ICB therapies and combination approaches that incorporate ICB technologies. This Review discusses our current knowledge of the immune response in thyroid cancers, the latest and ongoing immune-based approaches, and the future of immunotherapies in thyroid cancer. Physiologically relevant preclinical mouse models and human correlative research studies will inform development of the next stage of immune-based therapies for patients with advanced thyroid cancer.
引用
收藏
页码：629 / 641
页数：13
相关论文
共 166 条
[1]   Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature [J].
Adnane, Lila ;
Trail, Pamela A. ;
Taylor, Ian ;
Wilhelm, Scott M. .
REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 :597-+
[2]   Effectiveness of chemotherapy in advanced differentiated thyroid cancer: a systematic review [J].
Albero, Ana ;
Ester Lopez, Juliana ;
Torres, Alberto ;
de la Cruz, Luis ;
Martin, Tomas .
ENDOCRINE-RELATED CANCER, 2016, 23 (02) :R71-R84
[3]   Circulating Myeloid-Derived Suppressor Cells Predict Differentiated Thyroid Cancer Diagnosis and Extent [J].
Angell, Trevor E. ;
Lechner, Melissa G. ;
Smith, Alison M. ;
Martin, Sue E. ;
Groshen, Susan G. ;
Maceri, Dennis R. ;
Singer, Peter A. ;
Epstein, Alan L. .
THYROID, 2016, 26 (03) :381-389
[4]   MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro [J].
Angell, Trevor E. ;
Lechner, Melissa G. ;
Jang, Julie K. ;
LoPresti, Jonathan S. ;
Epstein, Alan L. .
CLINICAL CANCER RESEARCH, 2014, 20 (23) :6034-6044
[5]   BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration [J].
Angell, Trevor E. ;
Lechner, Melissa G. ;
Jang, Julie K. ;
Correa, Adrian J. ;
LoPresti, Jonathan S. ;
Epstein, Alan L. .
THYROID, 2014, 24 (09) :1385-1393
[6]  
[Anonymous], SEER cancer statistics review, 1975-2017
[7]   Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma [J].
Ascierto, Paolo Antonio ;
Ferrucci, Pier Francesco ;
Fisher, Rosalie ;
Del Vecchio, Michele ;
Atkinson, Victoria ;
Schmidt, Henrik ;
Schachter, Jacob ;
Queirolo, Paola ;
Long, Georgina V. ;
Di Giacomo, Anna Maria ;
Svane, Inge Marie ;
Lotem, Michal ;
Bar-Sela, Gil ;
Couture, Felix ;
Mookerjee, Bijoyesh ;
Ghori, Razi ;
Ibrahim, Nageatte ;
Moreno, Blanca Homet ;
Ribas, Antoni .
NATURE MEDICINE, 2019, 25 (06) :941-+
[8]   IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade [J].
Ayers, Mark ;
Lunceford, Jared ;
Nebozhyn, Michael ;
Murphy, Erin ;
Loboda, Andrey ;
Kaufman, David R. ;
Albright, Andrew ;
Cheng, Jonathan D. ;
Kang, S. Peter ;
Shankaran, Veena ;
Piha-Paul, Sarina A. ;
Yearley, Jennifer ;
Seiwert, Tanguy Y. ;
Ribas, Antoni ;
McClanahan, Terrill K. .
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) :2930-2940
[9]   Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma [J].
Bachleitner-Hofmann, Thomas ;
Friedl, Josef ;
Hassler, Michaela ;
Hayden, Hubert ;
Dubsky, Peter ;
Sachet, Monika ;
Rieder, Erwin ;
Pfragner, Roswitha ;
Brostjan, Christine ;
Riss, Stefan ;
Niederle, Bruno ;
Gnant, Michael ;
Stift, Anton .
ONCOLOGY REPORTS, 2009, 21 (06) :1585-1592
[10]   Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization [J].
Baitsch, Lukas ;
Legat, Amandine ;
Barba, Leticia ;
Marraco, Silvia A. Fuertes ;
Rivals, Jean-Paul ;
Baumgaertner, Petra ;
Christiansen-Jucht, Celine ;
Bouzourene, Hanifa ;
Rimoldi, Donata ;
Pircher, Hanspeter ;
Rufer, Nathalie ;
Matter, Maurice ;
Michielin, Olivier ;
Speiser, Daniel E. .
PLOS ONE, 2012, 7 (02)
12345678910